Cargando…

COVID-19 outcomes in persons with multiple sclerosis treated with rituximab

BACKGROUND: Outcomes of COVID-19 in PwMS (persons with Multiple Sclerosis) on immunosuppressive therapies, particularly B-cell depletors, can be unpredictable. There has been a concern for postponing or avoiding use of Rituximab (RTX) during the COVID-19 pandemic. We report the course and outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iyer, Rajesh B, S, Raghavendra, M, Javeria Nooraine, R, Jaychandran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579699/ https://www.ncbi.nlm.nih.gov/pubmed/35158435 http://dx.doi.org/10.1016/j.msard.2021.103371

Ejemplares similares

Clarithromycin-induced Seizures and Status Epilepticus
por: Seetharam, Raghavendra, et al.
Publicado: (2021)

Ictal PET in presurgical workup of refractory extratemporal epilepsy
por: Nooraine, Javeria, et al.
Publicado: (2013)

Posterior quadrant disconnection for refractory epilepsy: A case series
por: Nooraine, Javeria, et al.
Publicado: (2014)

Autosomal recessive bilateral frontal polymicrogyria with ectopia lentis and chorioretinal dystrophy
por: Nooraine, Javeria, et al.
Publicado: (2013)

Apomorphine: The Initial Indian Experience in Relation to Response Tests and Pumps
por: Prashanth, LK, et al.
Publicado: (2020)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Role of Electroencephalography in Presurgical Evaluation of Temporal Lobe Epilepsy
por: Raghavendra, Seetharam, et al.
Publicado: (2012)

Prolonged COVID-19 in a Multiple Sclerosis Patient Treated With Rituximab
por: Kintrilis, Nikos, et al.
Publicado: (2022)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021)

Serious safety events in rituximab‐treated multiple sclerosis and related disorders
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
por: Smith, Jessica B., et al.
Publicado: (2022)

Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021)

Impact of rituximab on COVID-19 outcomes
por: Levavi, Hannah, et al.
Publicado: (2021)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab
por: Tolf, Andreas, et al.
Publicado: (2022)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis
por: Vartzelis, George, et al.
Publicado: (2019)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)

Experience with long-term rituximab use in a multiple sclerosis clinic
por: Barra, Megan E, et al.
Publicado: (2016)

Evaluation of safety of rituximab in patients with multiple sclerosis: A retrograde study
por: Majdinasab, Nastaran, et al.
Publicado: (2020)

Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis
por: Salehizadeh, Saeideh, et al.
Publicado: (2022)

PROLONGED COVID-19 IN PATIENTS TREATED WITH RITUXIMAB
por: WEBER, ANDREW, et al.
Publicado: (2021)

Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate
por: Farley, Stephen, et al.
Publicado: (2019)

Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
por: Dorcet, Guillaume, et al.
Publicado: (2022)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Gascón-Giménez, Francisco, et al.
Publicado: (2023)

Clinical and radiologic outcomes in two patients with multiple sclerosis treated with tocilizumab for COVID-19
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
por: Jack, Dominic, et al.
Publicado: (2021)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Impact of vaccination on COVID‐19 outcome in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022)

The Psychological Impact of COVID-19 Pandemic on Persons with Multiple Sclerosis in Saudi Arabia
por: Alshammari, Ahmed N., et al.
Publicado: (2023)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ndfpccceegq7hj35ogv8cdl4b0